Moreover, a few studies have reported high expression of MAGE-D2 in other cancers, such as hepatocellular carcinoma (22), gastric cancer (23), glioma cancer, small intestinal carcinoid (24), and glioma (25). Here, MAGED2 is linked to central nervous system cancer.